Natural killer cells in patients with severe chronic fatigue syndrome.
Brenu, E W, Hardcastle, S L, Atkinson, G M et al. · Auto- immunity highlights · 2013 · DOI
Quick Summary
This review examined how natural killer (NK) cells—a type of white blood cell that fights infections and abnormal cells—work differently in ME/CFS patients. The researchers found that people with ME/CFS often have unusual numbers of NK cells or reduced ability to fight infections, which may help explain why patients suffer from persistent symptoms and recurrent infections. Understanding these immune cell problems could eventually lead to better treatments.
Why It Matters
NK cell dysfunction represents a measurable biological abnormality in ME/CFS that could objectively validate patient experiences of immune dysfunction and recurrent infections. Identifying specific NK cell defects may enable development of biomarkers for diagnosis, disease stratification by severity, and targeted immunotherapeutic interventions. This work bridges immune science and clinical ME/CFS, providing evidence that symptoms have biological underpinnings rather than psychosomatic origins.
Observed Findings
ME/CFS patients demonstrate abnormal natural killer cell counts—either elevated or reduced depending on disease subtype
Reduced NK cell cytotoxic activity (killing capacity) in many ME/CFS patients compared to healthy controls
Altered expression of NK cell receptors that regulate activation and inhibitory signals
Variable NK cell dysfunction correlating with symptom severity in some patient cohorts
Recurrent or persistent viral infections associated with impaired NK cell responses
Inferred Conclusions
Natural killer cell dysfunction is a consistent immunological abnormality across ME/CFS patient populations, though manifestations vary by disease severity
NK cell profiling may help identify and classify ME/CFS subtypes, supporting a biological basis for disease heterogeneity
Impaired NK cell-mediated immune responses could explain increased susceptibility to infections reported by ME/CFS patients
Remaining Questions
Are specific NK cell abnormalities present before disease onset (potential biomarkers) or only develop as disease progresses?
Which NK cell defects are primary disease drivers versus secondary consequences of prolonged illness?
What This Study Does Not Prove
This review does not prove that NK cell dysfunction causes ME/CFS or that correcting NK cell function will cure the disease. As a systematic review synthesizing existing studies, it cannot establish causation, and heterogeneity across studies prevents definitive conclusions about which specific NK abnormalities are primary versus secondary to other disease mechanisms. The findings do not rule out multi-system involvement or the possibility that NK dysfunction is one of several concurrent immune problems.